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An important component of the burden of
cardiovascular disease in low- and middle-income
countries may be attributed to the neglected tropical
diseases.
There is a growing awareness of the
importance of chronic non-communicable
diseases (CNCDs) in the world’s low- and
middle-income countries (LMICs). Begin-
ning in the 1990s, Murray and Lopez
predicted a doubling of death rates due to
cardiovascular disease in developing coun-
tries by 2020 [1], while a substantial rise
was also predicted by Leeder et al. [2].
Based on World Health Organization
(WHO) predictions, 75% of the burden
of cardiovascular disease is found in
LMICs [3]. Alarming increases have also
been noted for other CNCDs in LMICs
including cancer, chronic respiratory dis-
eases, and diabetes [4]. In September
2011, a report by the World Economic
Forum and the Harvard School of Public
Health estimated the global economic
burden of CNCDs over the next two
decades to be US$47 trillion [5]. During
this same month, the United Nations
General Assembly held a high-level meet-
ing to discuss prevention and control of
CNCDs, including cardiovascular diseas-
es, in LMICs [6]. These initiatives have
focused on preventable risk factors attrib-
utable to lifestyle changes such as tobacco
and alcohol use, prolonged unhealthy
nutrition, and physical inactivity, which
currently account for a high proportion of
cardiovascular deaths in North America
and Europe [4–6].
While there is no question that obesity,
tobacco, and alcohol represent major
underlying conditions responsible for the
rise of cardiovascular and other CNCDs in
LMICs, they do not provide a complete
picture. In March of 2011, Partners in
Health and Harvard Medical School spon-
sored a conference entitled ‘‘The Long Tail
of Global Health Equity: Tackling the
Endemic Non-Communicable Diseases of
the Bottom Billion’’ to examine in more
detail some of the neglected causes of
CNCDs, particularly those that are unique
to the world’s poorest people in LMICs.
The conference highlighted important risk
factors apart from the lifestyle changes
linked to CNCDs in high-income countries
[7]. Specifically with respect to neglected
populations, an important component of
cardiovascular disease may be attributable
to neglected tropical diseases (NTDs) and
other infections of poverty. For example,
the Heart of Soweto Study from South
Africa identified rheumatic heart disease,
tuberculosis, and HIV as significant con-
tributors to heart disease and more com-
mon than coronary artery disease. Even in
the urbanizedregionofSowetowherethere
is a high prevalence of vascular risk factors,
non-ischemic etiologies are still the domi-
nant cause of heart failure [8,9].
On a global level, the contribution of
infections of poverty to heart disease can
be seen in analyzing the Global Burden of
Disease estimates from the WHO. Ac-
cording to this data, approximately 8.8%
of the disability-adjusted life years
(DALYs) of LMICs may be attributable
to cardiovascular disease [3]. Almost one-
half of this cardiovascular disease burden
is attributable to ischemic heart disease,
more than one-third to cerebrovascular
disease, and the remainder to hypertensive
and inflammatory causes, as well as
rheumatic heart disease (Figure 1). A
detailed analysis of these conditions sug-
gests that NTDs and other neglected
infections may account for a significant
component of each of these cardiovascular
disease categories (Table 1).
Protozoan NTDs: American and
African Trypanosomiasis
Approximately 10 million people are
infected with Trypanosoma cruzi, the etio-
logic agent of Chagas disease (American
trypanosomiasis), of whom up to 30% will
develop Chagasic cardiomyopathy associ-
ated with heart failure, arrhythmias, and
mural thrombi causing pulmonary and
systemic emboli and sudden death [10–
14]. Chronic heart failure is thought to be
due to the persistence of trypanosome
amastigotes in the heart, leading to a
cascade of tissue destruction, myocarditis,
fibrosis, and ultimately ventricular dilation
[12]. Arrhythmias are similarly caused by
fibrosis. The arrhythmias then predispose
to various forms of emboli, and Chagas
disease has been linked to ischemia and
cerebrovascular disease and even stroke
[13,14]. Thus, roughly 2–3 million people
at any given time may be affected by
Chagas cardiomyopathy, which can pres-
ent either as ischemic or inflammatory
heart disease or with mixed features of
both [12–14]. While 99% of the DALYs
associated with Chagas disease have been
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Americas, the ‘‘globalization’’ of Chagas
disease from emigration is now recognized
as a factor in a previously hidden burden
of heart disease in the United States and
Europe, especially Spain [15]. Globally,
Chagas disease, therefore, accounts for a
significant burden of ischemic and inflam-
matory heart disease in LMICs of the
Americas and now accounts for an as yet
undefined burden in some high-income
countries as well. Similarly, human Afri-
can trypanosomiasis (HAT) can be associ-
ated with myocarditis and pericarditis,
especially in the acute stages of the illness
when the trypamastigote stages of the
parasite spread through the blood and
lymphatics to cause endarteritis [16]. On
electrocardiography repolarizaton chang-
es, prolonged QT intervals and low
voltage can be seen in infected individuals
[17]. About 50,000 to 70,000 people in
sub-Saharan Africa are thought to be
infected with Trypanosoma brucei, with an
annual incidence of approximately 17,000,
and of infected patients 70% develop the
above mentioned electrocardiographic
changes [17,18].
Helminthic NTDs:
Endomyocardial Fibrosis,
Schistosomiasis, and
Hookworm Infection
Endomyocardial fibrosis (EMF) causing
restrictive cardiomyopathy is most preva-
lent in tropical and subtropical regions in
the world. In endemic areas of sub-
Saharan Africa, the prevalence of EMF
reaches close to 20% and affects mostly
children and young adults [19,20]. EMF is
currently the fourth leading cause of heart
disease in Nigeria, Africa’s most populous
country [21,22]. EMF is also associated
with pericarditis, arrhythmias, and mural
thrombi [22,23]. The etiology of tropical
EMF remains unclear; however, a number
of factors and helminthic parasites have
been implicated in its pathogenesis, par-
ticularly because its occurrence has been
linked to eosinophilia and hypereosinophi-
lia [22,24]. For that reason, endemic
Figure 1. Distribution of DALYs attributed to cardiovascular disease among low- and
middle-income countries (LMICs). Data obtained from WHO 2008 Global Burden of Disease
estimates [3].
doi:10.1371/journal.pntd.0001499.g001
Table 1. Estimated Prevalence of Cardiovascular Disease Caused by Neglected Tropical Diseases and Neglected Infections of
Poverty.
NTD
Type of Cardiovascular
Disease
a
Estimated Number of
People with the Infection
Number of Cases of Heart Disease
or Related Conditions References
Chagas disease Ischemic, cerebrovascular, and
inflammatory
10 million 2–3 million [10–14]
HAT Inflammatory 50,000–70,000 in
sub-Saharan Africa
Not determined [16–18]
Toxoplasmosis Inflammatory Up to 77% seroprevalence
worldwide
19% of AIDS cardiomyopathy associated with
acute myocarditis
[50,67,68]
EMF Inflammatory 12 million All [23,58]
Schistosomiasis Inflammatory (cardiomyopathy) 200 million .270,000 with pulmonary hypertentsion [28–34]
Hookworm Inflammatory (CHF) 600 million Not determined [35–37,69]
Syphillis Inflammatory 12 million Untreated, 10% develop late cardiovascular
complications
[40,41,70]
Tuberculosis Inflammatory 2 billion (.10 million
coinfected with HIV)
1%–2% of people with pulmonary TB develop
TB pericarditis
[46,48,71]
HIV Inflammatory (pericarditis,
cardiomyopathy)
34 million people
worldwide with HIV
and AIDS
Pericarditis: 19%–32% of asymptomatic people
with AIDS not on HAART; Cardiomyopathy:
15%–57% of symptomatic and asymptomatic
people with AIDS not on HAART
[49,50]
Dengue Inflammatory 50–100 million cases
annually
Myocardial dysfunction in 6.7% with DF,
13.8% with DHF, 36% with DSS
[54–56,72,73]
Rheumatic heart disease Ischemic, cerebrovascular,
rheumatic
RF: Up to 206/100,000 in
developing world
RHD: Up to 18.6/100,000 in developing world [51,52,74]
aBased on WHO Global Burden of Disease categories.
NTD, neglected tropical disease; HAT, human African trypanosomiasis; AIDS, acquired immune deficiency syndrome; EMF, endomyocardial fibrosis; CHF, congestive
heart failure; HIV, human immunodeficiency virus; TB, tuberculosis; HAART, highly active antiretroviral therapy; DF, dengue fever; DHF, dengue hemorrhagic fever
without shock; DSS, dengue shock syndrome; RF, rheumatic fever; RHD, rheumatic heart disease.
doi:10.1371/journal.pntd.0001499.t001
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Loa loa and Onchocerca volvulus are among
the leading candidate infections linked to
this condition [22,25–27]. Two other
helminths, Schistosoma mansoni and Schisto-
soma japonicum, cause chronic hepatosplenic
schistosomiasis, an important cause of
pulmonary hypertension and cor pulmo-
nale. These pathologies occur in response
to parasite egg deposition, hepatosplenic
fibrosis, and portal hypertension [28–31].
Lapa et al. calculate that an estimated 200
million people worldwide are infected with
any Schistosoma species, of whom 4%–8%
develop hepatosplenic disease, and greater
than 270,000 will go on to develop
pulmonary artery hypertension [32].
However, more recently, King et al.
suggest that previous estimates have been
underestimating the true impact, and the
prevalence of schistosomiasis-related dis-
ease is closer to 400–600 million world-
wide [33]. Based on even the most
conservative estimates, schistosomiasis
may rank among the most prevalent
causes of pulmonary hypertension world-
wide [32,34]. Finally, among helminths
causing cardiovascular disease, hookworm
infection is a leading cause of iron
deficiency anemia in LMICs [35]. Recent
systematic reviews confirm strong links
between hookworm infection and anemia
among children and both pregnant and
non-pregnant adults [36,37]. In Africa and
Brazil, hookworm and S. mansoni schisto-
somiasis were shown to be synergistic [38].
Severe anemia is an important co-factor in
congestive heart failure, although the
contribution of hookworm disease and
anemia to this condition is unknown.
Bacterial and Viral NTDs and
Neglected Bacterial Infections
In their first ever report on NTDs in
2010, the WHO classified the endemic
treponematoses, including Trepomema palli-
dum (the cause of syphilis), as NTDs [39].
Late cardiovascular complications of syph-
ilis, affecting 10% of untreated cases, cause
obliterative endarteritis leading to syphi-
litic aortitis. The complications of syphi-
litic aortitis are coronary artery disease,
valvular disease, and left ventricular vol-
ume overload hypertrophy [40]. A recent
study in India assessing the prevalence of
syphilitic aortitis in non-atherosclerotic
aortic disease found 23% of aortic disease
to be due to syphilis [41]. Tertiary syphilis
can also, less commonly, cause gumma-
tous myocarditis [42]. Of note, however,
cardiovascular syphilis is considered a rare
disease in developed countries [43]. A
more ubiquitous bacteria, Mycobacterium
tuberculosis, leads to another cardiac man-
ifestation, tuberculous pericarditis. Among
patients with pulmonary tuberculosis, 1%
to 2% develop tuberculous pericarditis.
The various manifestations can include
myopericarditis, pericardial constriction,
pericardial effusion, and effusive-constric-
tive pericarditis [31]. In sub-Saharan
Africa, 70% to 90% of large pericardial
effusions and 10% of cases of congestive
heart failure are caused by M. tuberculosis
[31,44,45]. While the vast majority of
cases of tuberculosis occur in developing
countries, it is also seen in immigrant
populations of developed countries, and
thus the prevalence of tuberculous peri-
carditis reflects this distribution [46,47].
The disease is frequently diagnosed in
HIV-positive patients, and when it is, it
carries a mortality rate of 40% in 6
months compared to 17% in those without
co-morbid HIV infection [48]. This form
of pericarditis is associated with significant
morbidity and mortality due to the
effusions and constriction that occur
despite appropriate medical therapy [48].
In the absence of M. tuberculosis, untreated
HIV can still cause pericarditis as well as
other forms of cardiovascular disease,
including pulmonary hypertension and
cardiomyopathy [49]. In Africa, toxoplas-
mosis and cryptococcosis are also impor-
tant opportunistic infections associated
with cardiomyopathy [50]. Finally, 80%
of rheumatic heart disease associated with
group A streptococcal infection occurs in
LMICs [51]. The WHO data depicted in
Figure 2 demonstrate the skewed burden
weighted toward LMICs of the world,
specifically in the Middle East and Asia,
where substantially higher disease burdens
(as measured in DALYs) exist [3]. These
projections likely even underestimate the
true burden of disease based on recent
evidence [51]. The weighted burden
toward LMICs is a relatively new phe-
nomenon. Prior to the 1970s, rheumatic
fever was an important cause of morbidity
in developed countries; however, in the
1970s and 1980s, the prevalence of
rheumatic fever began to decrease, while
the rates in developing countries are an
ongoing challenge and contribute signifi-
cantly to the burden of disease [52]. The
inequity between the wealthy and the poor
can be seen even in high-income countries
today where rheumatic heart disease
disproportionately affects people living in
poverty and indigenous populations
[51,53]. Without adequate treatment, the
mitral valve abnormalities characteristic of
rheumatic heart disease predispose pa-
tients to other cardiac pathologies such as
infectious endocarditis [8], thus making
rheumatic heart disease a contributing
factor to both ischemic and cerebrovascu-
lar disease. Among the viral NTDs, most
notably dengue fever has been associated
with systolic and diastolic cardiac impair-
ments [54], as well as myocarditis [55,56].
Policy Recommendations
We lack adequate data to determine the
true extent of human cardiovascular
disease that results from NTDs and other
neglected infections of poverty. It also
remains unclear how much of the world’s
ischemic heart disease and cerebrovascu-
lar disease, which account for most of the
disease burden, may be due to neglected
causes. There is an urgent need to
understand the contribution of neglected
diseases to heart disease in LMICs in order
to design appropriate intervention strate-
gies. This has been highlighted by others
in the field who also acknowledge the
presence of unique risk factors and heart
pathologies in LMICs [8,11,20,31,57,58].
Towards that goal, stepped up measures
for some of the neglected parasitic diseases
might include increased screening for
Chagas disease in the Americas (including
the United states), Europe, and elsewhere
using antibody-based testing now available
[59], Doppler testing for pulmonary hy-
pertension that results from schistosomiasis
in Africa, and investigations into the
etiology of EMF, especially tropical EMF
linked to eosinophilia. Similarly, the extent
to which bacterial infections such as
syphilis, tuberculous pericarditis, and
rheumatic heart disease (RHD) contribute
to cardiovascular disease in LMICs re-
mains unclear and requires improved
diagnostic capabilities and testing. For
RHD in particular, echocardiographic
screening in school-aged populations is
recognized as an important method of
identifying subclinical rheumatic heart
disease in the early stages prior to the
progression to heart failure [53]. Such
diagnostics and testing requires improved
health systems in the developing world.
Bukhman and Kidder have outlined novel
methods of integrating services for RHD
and heart failure into existing health
systems in LMICs [60,61]. This can be
expanded upon and tailored to specific
regions.
There also remains a dearth of ade-
quate control tools, that is, new drugs or
vaccines for the neglected causes of human
cardiovascular disease in LMICs. For
instance, benznidazole and nifurtimox,
the currently available drugs for treating
Chagasic cardiomyopathy, require long
treatment courses, and exhibit high levels
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ing parasitologic cure is also in doubt and
complicated by the absence of adequate
biomarkers for assessing either progression
of disease or clinical outcomes [63,64]. As
an alternative intervention, efforts are in
progress to develop and test therapeutic
vaccines for Chagas disease [64]. Without
a clear etiology, interventions for EMF
beyond palliative surgeries for restrictive
cardiomyopathy will be difficult to develop
and test, while for schistosomiasis and
hookworm there are needs to greatly
expand coverage for annual mass drug
administration using currently available
anthelminthic drugs, as well as develop
new anthelminthic vaccines to prevent
anemia and heart disease, and forestall
drug resistance [38]. For neglected bacte-
rial infections, there is a need to accelerate
new vaccines for tuberculosis [65,66] and
RHD [57] now in different stages of
development, while the incidence of syph-
ilis-associated heart disease may be re-
duced through expanded drug coverage.
Finally, as identified by Commerford
and Mayosi, when the etiology and control
mechanisms are known, research should
include identifying social determinants
that prevent disease management. Social
determinants such as health systems,
attitudes, and perceptions of both patients
and physicians and socioeconomic factors
should all be explored and recognized as
important aspects of cardiovascular dis-
ease control and variable between ethnic
groups [8]. With all the information
gathered, the cost of prevention and
control can be compared to the burden
cost of the various causes of cardiovascular
disease in LMICs.
Together, these interventions will ad-
dress significant neglected causes of car-
diovascular disease burden especially prev-
alent in LMICs. The growing interest in
cardiovascular disease in these resource-
poor settings is necessary to ensuring the
health of the working-age population.
Careful analysis reveals the need to look
beyond lifestyle risk factors of developed
countries and appreciate the nuances of
chronic disease in developing countries. In
doing so, we will more effectively facilitate
the economic advancement of low- and
middle-income populations.
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